| MeSH term | MeSH ID | Detail |
|---|---|---|
| Myxoma | D009232 | 1 associated lipids |
| Kleine-Levin Syndrome | D017593 | 1 associated lipids |
clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- J. Antimicrob. Chemother. (1)
- Clin. Diagn. Lab. Immunol. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Torgano G et al. | Treatment of Helicobacter pylori and Chlamydia pneumoniae infections decreases fibrinogen plasma level in patients with ischemic heart disease. | 1999 | Circulation | pmid:10096930 |
| Navuluri R and Yue S | Understanding peptic ulcer disease pharmacotherapeutics. | 1999 | Nurse Pract | pmid:10100245 |
| Fournier S et al. | Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients. | 1999 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10192709 |
| Gómez-Gil E et al. | Clarithromycin-induced acute psychoses in peptic ulcer disease. | 1999 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10192720 |
| Lee CK et al. | Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. | 1999 | Vaccine | pmid:10195786 |
| Bartnof HS | OIs and cancers. | 1999 | BETA | pmid:11367262 |
| Gimenez Garcia R et al. | Fish tank granuloma: response to treatment with clarithromycin. | 1999 | J Eur Acad Dermatol Venereol | pmid:10188167 |
| Dubé MP et al. | Successful short-term suppression of clarithromycin-resistant Mycobacterium avium complex bacteremia in AIDS. California Collaborative Treatment Group. | 1999 | Clin. Infect. Dis. | pmid:10028084 |
| Moreau P et al. | Lack of efficacy of clarithromycin in advanced multiple myeloma. Intergroupe Français du Myélome (IFM) | 1999 | Leukemia | pmid:10086745 |
| Unge P | Antibiotic treatment of Helicobacter pylori infection. | 1999 | Curr. Top. Microbiol. Immunol. | pmid:10087665 |
| Wreiber K et al. | [Development of resistant Helicobacter pylori in Sweden. Tendency toward increasing resistance to clarithromycin]. | 1999 | Lakartidningen | pmid:10087796 |
| Sakatani M | [Multi-drug resistant mycobacterial infection]. | 1999 | Ryoikibetsu Shokogun Shirizu | pmid:10088372 |
| GarcÃa-Romero E et al. | [Treatment with omeprazole, clarithromycin and amoxicillin over 6 days in patients with Helicobacter pylori-infected duodenal ulcer]. | 1999 | Gastroenterol Hepatol | pmid:10089703 |
| Shirtliff ME et al. | Oral rifampin plus azithromycin or clarithromycin to treat osteomyelitis in rabbits. | 1999 | Clin. Orthop. Relat. Res. | pmid:10078148 |
| Ong EL | Prophylaxis against disseminated Mycobacterium avium complex in AIDS. | 1999 | J. Infect. | pmid:10090497 |
| Goldberg EI et al. | Henoch-Schönlein purpura induced by clarithromycin. | 1999 | Int. J. Dermatol. | pmid:10517691 |
| Uygun A et al. | Low efficacy of ranitidine bismuth citrate plus clarithromycin combination on Helicobacter pylori in a Turkish population. | 1999 | Am. J. Gastroenterol. | pmid:10520880 |
| Gibson JR et al. | Novel method for rapid determination of clarithromycin sensitivity in Helicobacter pylori. | 1999 | J. Clin. Microbiol. | pmid:10523591 |
| Osato MS et al. | Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. | 1999 | Int. J. Antimicrob. Agents | pmid:10493611 |
| Hirsh DC and Jang SS | Antimicrobial susceptibility of Nocardia nova isolated from five cats with nocardiosis. | 1999 | J. Am. Vet. Med. Assoc. | pmid:10496134 |
| Ellenrieder V et al. | Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. | 1999 | Scand. J. Gastroenterol. | pmid:10499474 |
| Harris A | The importance of clarithromycin dose in the management of H. pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. | 1999 | Aliment. Pharmacol. Ther. | pmid:10594406 |
| Gomollón F et al. | Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. | 1999 | Helicobacter | pmid:10597390 |
| Landesman KA et al. | Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics. | 1999 | Conn Med | pmid:10500341 |
| Auclair B et al. | Potential interaction between itraconazole and clarithromycin. | 1999 | Pharmacotherapy | pmid:10600094 |
| Unge P | The OAC and OMC options. | 1999 | Eur J Gastroenterol Hepatol | pmid:10503817 |
| Feldman M et al. | Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux. | 1999 | Am. J. Physiol. | pmid:10600812 |
| Spiller RC | Is there any difference in Helicobacter pylori eradication rates in patients with active peptic ulcer, inactive peptic ulcer and functional dyspepsia? | 1999 | Eur J Gastroenterol Hepatol | pmid:10503819 |
| Mégraud F | Resistance of Helicobacter pylori to antibiotics: the main limitation of current proton-pump inhibitor triple therapy. | 1999 | Eur J Gastroenterol Hepatol | pmid:10503821 |
| Sainz R et al. | [Helicobacter pylori infection. The Spanish consensus report. The Spanish Consensus Conference Group]. | 1999 | Rev Esp Enferm Dig | pmid:10601771 |
| Bazzoli F et al. | What can be learnt from the new data about antibiotic resistance? Are there any practical clinical consequences of Helicobacter pylori antibiotic resistance? | 1999 | Eur J Gastroenterol Hepatol | pmid:10503822 |
| Gisbert JP et al. | Re-treatment after Helicobacter pylori eradication failure. | 1999 | Eur J Gastroenterol Hepatol | pmid:10503846 |
| Giacometti A et al. | In vitro anticryptosporidial activity of ranalexin alone and in combination with other peptides and with hydrophobic antibiotics. | 1999 | Eur. J. Clin. Microbiol. Infect. Dis. | pmid:10614961 |
| Geiderman JM | Central nervous system disturbances following clarithromycin ingestion. | 1999 | Clin. Infect. Dis. | pmid:10476775 |
| Kohyama T et al. | Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. | 1999 | Antimicrob. Agents Chemother. | pmid:10103198 |
| Lugannani C and Strickland C | Empiric eradication therapy or endoscopy in Helicobacter pylori-positive patients? | 1999 | J Fam Pract | pmid:10628582 |
| GarcÃa-Arata MI et al. | Mutations in 23S rRNA in Helicobacter pylori conferring resistance to erythromycin do not always confer resistance to clarithromycin. | 1999 | Antimicrob. Agents Chemother. | pmid:9925537 |
| Blondon H | [Eradication of Helicobacter pylori: what is the effect on symptoms of non-ulcerous dyspepsia?]. | 1999 | Presse Med | pmid:10629694 |
| Uygun A et al. | Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population. | 1999 | Clin Ther | pmid:10509849 |
| Cammarota G et al. | Six-day or seven-day regimens with ranitidine bismuth citrate plus high-dose clarithromycin and tinidazole are both effective against Helicobacter pylori infection. | 1999 | Dig. Dis. Sci. | pmid:10630486 |
| Bortolotti M et al. | Effect of intravenous clarithromycin on interdigestive gastroduodenal motility of patients with functional dyspepsia and Helicobacter pylori gastritis. | 1999 | Dig. Dis. Sci. | pmid:10630494 |
| Furuta T et al. | Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. | 1999 | Clin. Pharmacol. Ther. | pmid:10511062 |
| Sharma VK et al. | A survey of gastroenterologists' perceptions and practices related to Helicobacter pylori infection. | 1999 | Am. J. Gastroenterol. | pmid:10566709 |
| Fattorini L et al. | Activities of eighteen antimicrobial regimens against Mycobacterium avium infection in beige mice. | 1999 | Microb. Drug Resist. | pmid:10566874 |
| Juurlink DN and Ito S | Comment: clarithromycin-digoxin interaction. | 1999 | Ann Pharmacother | pmid:10630847 |
| Talley NJ et al. | Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. | 1999 | N. Engl. J. Med. | pmid:10511608 |
| Lamouliatte H et al. | Double vs. single dose of pantoprazole in combination with clarithromycin and amoxycillin for 7 days, in eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. | 1999 | Aliment. Pharmacol. Ther. | pmid:10571611 |
| Baylor P and Williams K | Interstitial nephritis, thrombocytopenia, hepatitis, and elevated serum amylase levels in a patient receiving clarithromycin therapy. | 1999 | Clin. Infect. Dis. | pmid:10525003 |
| Stengel W | [Sporotrichoid mycobacteriosis caused by Mycobacterium marinum]. | 1999 | Dtsch. Med. Wochenschr. | pmid:10572519 |
| Madsen LG et al. | Ménétrier's disease and Helicobacter pylori: normalization of gastrointestinal protein loss after eradication therapy. | 1999 | Dig. Dis. Sci. | pmid:10573379 |
| Furusyo N et al. | Rapidly growing primary gastric B-cell lymphoma after eradication of Helicobacter pylori. | 1999 | Intern. Med. | pmid:10526942 |
| Semret M et al. | Mycobacterium ulcerans infection (Buruli ulcer): first reported case in a traveler. | 1999 | Am. J. Trop. Med. Hyg. | pmid:10586895 |
| Chérin P et al. | Macrophagic myofasciitis: improvement with antibiotic therapy. | 1999 | J. Rheumatol. | pmid:10529163 |
| Nasu T et al. | [In vitro antibacterial activity of faropenem, a novel oral penem antibiotic, against enterohemorrhagic Escherichia coli O157 strains]. | 1999 | Jpn J Antibiot | pmid:10587879 |
| Moola S et al. | A multicenter study of grepafloxacin and clarithromycin in the treatment of patients with community-acquired pneumonia. | 1999 | Chest | pmid:10531162 |
| Langan CE et al. | Randomized, double-blind study of short-course (5 day) grepafloxacin versus 10 day clarithromycin in patients with acute bacterial exacerbations of chronic bronchitis. | 1999 | J. Antimicrob. Chemother. | pmid:10588313 |
| Unal M et al. | Ocular toxicity of intravitreal clarithromycin. | 1999 | Retina (Philadelphia, Pa.) | pmid:10546942 |
| Rodvold KA | Clinical pharmacokinetics of clarithromycin. | 1999 | Clin Pharmacokinet | pmid:10589373 |
| Woo PC et al. | Antibiotics modulate vaccine-induced humoral immune response. | 1999 | Clin. Diagn. Lab. Immunol. | pmid:10548572 |
| Adamsson I et al. | Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients. | 1999 | J. Antimicrob. Chemother. | pmid:10552979 |
| Cirioni O et al. | In-vitro activity of rifabutin and albendazole singly and in combination with other clinically used antimicrobial agents against Pneumocystis carinii. | 1999 | J. Antimicrob. Chemother. | pmid:10552982 |
| Owen RJ et al. | Effect of clarithromycin and omeprazole therapy on the diversity and stability of genotypes of Helicobacter pylori from duodenal ulcer patients. | 1999 | Microb. Drug Resist. | pmid:10432275 |
| Calvet X et al. | Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383508 |
| Sieg A et al. | Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate Helicobacter pylori. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383519 |
| Grimley CE et al. | Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383520 |
| Houben MH et al. | Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains. | 1999 | Aliment. Pharmacol. Ther. | pmid:10383522 |
| Tomiyama Y et al. | [The combination therapy of clarithromycin and sparfloxacin for pulmonary Mycobacterium gordonae infection]. | 1999 | Kekkaku | pmid:10386036 |
| Katsura Y et al. | Anti-Helicobacter pylori agents. 3. 2-[(Arylalkyl)guanidino]-4-furylthiazoles. | 1999 | J. Med. Chem. | pmid:10425101 |
| Marini RP et al. | Ranitidine bismuth citrate and clarithromycin, alone or in combination, for eradication of Helicobacter mustelae infection in ferrets. | 1999 | Am. J. Vet. Res. | pmid:10791942 |
| Williams SL et al. | Development of a firefly luciferase-based assay for determining antimicrobial susceptibility of Mycobacterium avium subsp. paratuberculosis. | 1999 | J. Clin. Microbiol. | pmid:9889208 |
| Grimm KJ | Treatment of Helicobacter pylori infection in functional dyspepsia. | 1999 | J Fam Pract | pmid:10428242 |
| Savarino V et al. | Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection. | 1999 | Aliment. Pharmacol. Ther. | pmid:9892878 |
| Gooch WM et al. | Loracarbef versus clarithromycin in children with acute otitis media with effusion. | 1999 | Clin Ther | pmid:10363736 |
| Moshkowitz M et al. | The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia. | 1999 | J Am Geriatr Soc | pmid:10366173 |
| Wimsatt JH et al. | Clarithromycin pharmacokinetics in the desert tortoise (Gopherus agassizii). | 1999 | J. Zoo Wildl. Med. | pmid:10367642 |
| McConnell SA and Amsden GW | Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin. | 1999 | Pharmacotherapy | pmid:10212011 |
| Dubois J and St-Pierre C | In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species. | 1999 | Diagn. Microbiol. Infect. Dis. | pmid:10212753 |
| Son SW et al. | The response of rosacea to eradication of Helicobacter pylori. | 1999 | Br. J. Dermatol. | pmid:10354058 |
| Pilotto A et al. | Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients. | 1999 | J. Gastroenterol. Hepatol. | pmid:10355512 |
| Jacoby EB and Porter KB | Helicobacter pylori infection and persistent hyperemesis gravidarum. | 1999 | Am J Perinatol | pmid:10355915 |
| Fost DA et al. | Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy. | 1999 | J. Allergy Clin. Immunol. | pmid:10359882 |
| Bhasin DK et al. | Helicobacter pylori eradication: comparison of three treatment regimens in India. | 1999 | J. Clin. Gastroenterol. | pmid:10372934 |
| Behrens R et al. | Dual versus triple therapy of Helicobacter pylori infection: results of a multicentre trial. | 1999 | Arch. Dis. Child. | pmid:10373140 |
| Masa K et al. | Effect of clarithromycin and other macrolides on the sulfoxidation and 5-hydroxylation of lansoprazole in dogs. | 1999 | Biol. Pharm. Bull. | pmid:10375172 |
| Bamford JT et al. | Effect of treatment of Helicobacter pylori infection on rosacea. | 1999 | Arch Dermatol | pmid:10376693 |
| Delle Cave M et al. | Seven days of ranitidine bismuth citrate plus two antimicrobials for Helicobacter pylori eradication. | 1999 | Ital J Gastroenterol Hepatol | pmid:10379492 |
| Schubert ML | H. pylori and nonulcer dyspepsia: not guilty as charged. | 1999 | Gastroenterology | pmid:10381939 |
| Yonemochi E et al. | Physicochemical properties of amorphous clarithromycin obtained by grinding and spray drying. | 1999 | Eur J Pharm Sci | pmid:9971917 |
| Realdi G et al. | Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. | 1999 | Helicobacter | pmid:10382124 |
| Piquette RK | Torsade de pointes induced by cisapride/clarithromycin interaction. | 1999 | Ann Pharmacother | pmid:9972380 |
| Principi N and Esposito S | Comparative tolerability of erythromycin and newer macrolide antibacterials in paediatric patients. | 1999 | Drug Saf | pmid:9935275 |
| Burgess DS et al. | A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance. | 1999 | Ann Pharmacother | pmid:10630825 |
| Allevi P et al. | A new convenient transformation of erythromycin A into clarithromycin. | 1999 | Bioorg. Med. Chem. | pmid:10658579 |
| Kamochi H et al. | Clarithromycin associated with torsades de pointes. | 1999 | Jpn. Circ. J. | pmid:10943628 |
| Smoot DT et al. | Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. | 1999 | Am. J. Gastroenterol. | pmid:10201463 |
| Laine L et al. | Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. | 1999 | Am. J. Gastroenterol. | pmid:10201465 |
| Khan AA et al. | Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. | 1999 | Int. J. Antimicrob. Agents | pmid:10221415 |
| Periti P and Mazzei T | Clarithromycin: pharmacokinetic and pharmacodynamic interrelationships and dosage regimen. | 1999 | J Chemother | pmid:10078776 |
| Sunazuka T et al. | Effects of erythromycin and its derivatives on interleukin-8 release by human bronchial epithelial cell line BEAS-2B cells. | 1999 | J. Antibiot. | pmid:10092202 |
| Garey KW et al. | Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. | 1999 | Antimicrob. Agents Chemother. | pmid:10223928 |